Restricted accessResearch articleFirst published online 2018-4
Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis
This systematic review and meta-analysis tries to determine whether there is an association between the use of protease inhibitors (PIs) and the incidence of diabetes mellitus (DM) and/or metabolic syndrome (MS) in HIV-infected patients. A systematic literature search was performed using MEDLINE/PubMed, CENTRAL, LILACS, and EMBASE. Included articles were observational studies published on or prior to November 2015 that met specific inclusion criteria. Pooled relative risks (RRs) and hazard ratios (HRs) were calculated. Nine articles met the inclusion criteria, describing 13,742 HIV patients. Use of PIs was associated with the development of MS (RR: 2.11; 95% CI 1.28–3.48; p-value 0.003). No association between the use of PIs and development of DM was found: the HR for the incidence of DM among patients using PIs was 1.23 (95% CI 0.66–2.30; p-value: 0.51) and the RR was 1.25 (95% CI 0.99–1.58; p-value 0.06). Use of PIs in HIV-infected patients is associated with an increased risk of MS. No evidence of an increased risk of DM was found. However, because MS is a precursor to DM, it is possible that studies with a longer follow-up duration are needed in order to detect an association between PI use and onset of DM.
MocroftAVellaSBenfieldTLet al.
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet1998;
352: 1725–1730.
3.
KrentzHBKliewerG andGillMJ.Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.HIV Med2005;
6: 99–106.
4.
PalellaFJJrBakerRKMoormanACet al.
Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.J Acquir Immune Defic Syndr2006;
43: 27–34.
5.
GranichRCrowleySVitoriaMet al.
Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update.Curr Opin HIV AIDS2010;
5: 298–304.
6.
MooreRD andChaissonRE.Natural history of HIV infection in the era of combination antiretroviral therapy.AIDS1999;
13: 1933–1942.
7.
PaikIJ andKotlerDP.The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection.Best Pract Res Clin Endocrinol Metab2011;
25: 469–478.
8.
ButtAAMcGinnisKRodriguez-BarradasMCet al.
HIV infection and the risk of diabetes mellitus.AIDS2009;
23: 1227–1234.
9.
BarbaroG andIacobellisG.Metabolic syndrome associated with HIV and highly active antiretroviral therapy.Curr Diab Rep2009;
9: 37–42.
10.
NixLM andTienPC.Metabolic syndrome, diabetes, and cardiovascular risk in HIV.Curr HIV/AIDS Rep2014;
11: 271–278.
National Cholesterol Education Program (NCEP) Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation2002; 106: 3143–3421.
13.
WannametheeSGShaperAGLennonLet al.
Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus.Arch Intern Med2005;
165: 2644–2650.
14.
KaurJ.A comprehensive review on metabolic syndrome.Cardiol Res Pract2014;
2014: 943162.
15.
BrownTTColeSRLiXet al.
Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study.Arch Intern Med2005;
165: 1179–1184.
16.
SamarasKWandHLawMet al.
Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.Diabetes Care2007;
30: 113–119.
17.
CohenMSChenYQMcCauleyMet al.
Prevention of HIV-1 infection with early antiretroviral therapy.N Engl J Med2011;
365: 493–505.
18.
ZolopaAAndersenJPowderlyWet al.
Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.PLoS One2009;
4: e5575.
19.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDSinfo, Department of Health and Human Services, 2009, pp.100–161.
20.
HurwitzBEKlimasNGLlabreMMet al.
HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk: role of protease inhibitor exposure.Cardiovasc Toxicol2004;
4: 303–316.
21.
HruzPW.Molecular mechanisms for insulin resistance in treated HIV-infection.Best Pract Res Clin Endocrinol Metab2011;
25: 459–468.
22.
ZhaBSWanXZhangXet al.
HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes.PLoS One2013;
8: e59514.
23.
HreskoRC andHruzPW.HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4.PLoS One2011;
6: e25237.
24.
SchuttMZhouJMeierMet al.
Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.J Endocrinol2004;
183: 445–454.
25.
AlmeidaSEBorgesMFiegenbaumMet al.
Metabolic changes associated with antiretroviral therapy in HIV-positive patients.Rev Saude Publica2009;
43: 283–290.
26.
De WitSSabinCAWeberRet al.
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.Diabetes Care2008;
31: 1224–1229.
27.
TienPCSchneiderMFColeSRet al.
Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women’s Interagency HIV Study.AIDS2007;
21: 1739–1745.
HigginsJPThompsonSGDeeksJJet al.
Measuring inconsistency in meta-analyses.BMJ2003;
327: 557–560.
32.
RezaianzadehANamayandehSM andSadrSM.National Cholesterol Education Program Adult Treatment Panel III Versus International Diabetic Federation Definition of Metabolic Syndrome, which one is associated with diabetes mellitus and coronary artery disease?Int J Prev Med2012;
3: 552–558.
33.
GrundySM.Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds.J Am Coll Cardiol2006;
47: 1093–1100.
34.
YeniPCooperDAAboulkerJPet al.
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.Lancet2006;
368: 287–298.
35.
The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Denmark: Center for Health & Infectious Disease Research (CHIP), http://www.chip.dk/Ongoing-Studies/DAD/About (accessed October 2015).
36.
PetoumenosKWormSWFontasEet al.
Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.J Int AIDS Soc2012;
15: 17426.
37.
FordESLiC andSattarN.Metabolic syndrome and incident diabetes: current state of the evidence.Diabetes Care2008;
31: 1898–1904.
38.
DayCaB andCliffordJ. Obesity in the pathogenesis of type 2 diabetes. Br J Diab Vasc Dis2011; 11: 55–61.
39.
GustafsonBHammarstedtAAnderssonCXet al.
Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis.Arterioscler Thromb Vasc Biol2007;
27: 2276–2283.
40.
NathanDMDavidsonMBDeFronzoRAet al.
Impaired fasting glucose and impaired glucose tolerance: implications for care.Diab Care2007;
30: 753–759.
41.
BarbaraA. The natural history of type 2 diabetes: practical points to consider in developing prevention and treatment strategies. Clin Diab2000; 18: 80–84.
42.
DeeksSG andPhillipsAN.HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity.BMJ2009;
338: a3172.
ErlandsonKMKitchDTierneyCet al.
Impact of randomized antiretroviral therapy initiation on glucose metabolism.AIDS2014;
28: 1451–1461.
45.
LedergerberBFurrerHRickenbachMet al.
Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study.Clin Infect Dis2007;
45: 111–119.
46.
EggerMDavey SmithGSchneiderMet al.
Bias in meta-analysis detected by a simple, graphical test.BMJ1997;
315: 629–634.
47.
HigginsJ andGreenS. Cochrane handbook for systematic reviews of interventions, version 5.1.0. [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org (accessed August 2015).
48.
SmithJM andFlexnerC.The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development.AIDS2017;
31: S173–S184.
49.
BustiAJBedimoRMargolisDMet al.
Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.J Investig Med2008;
56: 539–544.
50.
Bonfanti P, De Socio GV, Ricci E, et al. The feature of metabolic syndrome in HIV naive patients is not the same of those treated: results from a prospective study. Biomed Pharmacother 2012; 66: 348–353.
51.
Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006; 43: 458–466.
52.
Palacios R, Merchante N, Macias J, et al. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther 2006; 11: 529–535.
53.
Capeau J, Bouteloup V, Katlama C, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. Aids 2012; 26: 303–314.
54.
Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 298–302.
55.
Riyaten P, Salvadori N, Traisathit P, et al. New-Onset Diabetes and Antiretroviral Treatments in HIV-Infected Adults in Thailand. J Acquir Immune Defic Syndr 2015; 69: 453–459.
56.
Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. Aids 2007; 21: 1739–1745.
57.
Tripathi A, Liese AD, Jerrell JM, et al. Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: the impact of clinical and therapeutic factors over time. Diabet Med 2014; 31: 1185–1193.
58.
Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. Aids 2007; 21: 2445–2453.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
